Today we announced our Q1 2024 financial results. Our CEO, Tim Dyer, and Head of Translational Science, Mikhail Kalinichev, will host a conference call later today at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) to provide an update on business progress and a review of the Addex pipeline. #allostericmodulators #drugdevelopment #financialresults https://lnkd.in/dsNymquj
Addex Therapeutics’ Post
More Relevant Posts
-
Following recent news from Charles River Laboratories, regarding their continued investment into their Alternative Methods Advancement Project (AMAP), to reduce reliance on animal testing - we are thrilled to share a collaborative #genotoxicity publication between CRL, CN Bio and TwinStrand Biosciences. The publication demonstrates that Liver-on-a-chip is a promising tool for genotoxicity assessment. Click the link to learn more & congrats to all involved! #animalalternatives #organonchip #microphysiologicalsystem
I'm very excited to share our recent publication using our PhysioMimix platform to develop a genotoxicity application as a fantastic collaboration between CN Bio , Charles River Laboratories and TwinStrand Biosciences https://lnkd.in/eT6AdJyY It was a pleasure working with Benjamin Kopp , Annie Hamel , Thalita Boldrin Zanoni, PhD and the rest of the team at Charles River and TwinStrand. And a huge thanks to Raul Silva and Caitlin Rore who did most of the actual hard work at CN Bio and Tomasz Kostrzewski and Emily Richardson for their support. #OrganOnAChip #Genotox #NAM #MPS
-
-
To anyone looking to design a clinical trial, I highly recommend engaging with the Exploristics team (Aiden Flynn, Jamie Inshaw, Alessandra B.). Like many, I thought we "only" needed a power calculation for our Phase2b, but there is a much smarter way towards efficient design and our collaboration successfully got us there. thanks again, Exploristics | Transforming Clinical Trial Design
We're pleased to announce the conclusion of our successful #collaboration with Exploristics | Transforming Clinical Trial Design to enhance the design of the upcoming Phase IIb #clinicaltrial for our lead candidate, EXN407. Using Exploristics’ innovative study simulation software platform, KerusCloud, we were able to enhance the efficiency of our upcoming clinical programme with a data-driven approach. The Phase IIb study is planned to initiate in 2024, following the successful completion of a Phase Ib/IIa study in September 2023. The study concluded that EXN407 met all pharmacokinetic and safety parameters, as well as showing encouraging signs of biological activity as a novel topical treatment for diabetic #macularedema. Read the full announcement: https://rb.gy/b98y76
-
-
Connecting the dots to uncover and cultivate cognitive connections that ignite life-saving transformations. Championing #lifescience #climatetech #digitalhealth and #healthinnovation.
One of the #lifescience sector's most important voices in understanding the economic value of #patientcentricity - Jen Horonjeff - “Ask Patients”! Whenever we connect, I feel the #biopharma industry can realize its greater potential. Here at Scope Summit #SCOPEsummit.
-
-
Lipum to participate in the following upcoming events and meetings: NLSDays | 18-19 September | Malmö BioEurope | 4-6 November | Stockholm Redeye Autoinflammatory day | 20 November | Stockholm BioStockSummit | 20-21 November| Lund "These meetings provide a good opportunity for us to present and discuss our progress and results from our first clinical phase 1 study, to share our ongoing plans as well as presenting key milestones and triggers with investors and partners" says CEO Ola Sandborgh. #lipum #investorrelations #lifescience
-
-
RESISTANCE IS NOT AN OPTION
Omnix Medical will be at Biocom Global Life Science Partnering & Investor Conference, Feb 27-29 in Torrey Pines. Reach out for a discussion with our CEO Moshik Cohen-Kutner and CSO Niv Bachnoff, who will also be presenting at the conference. #BiocomGPIC Biocom California
-
-
Read key results from the GATHER1 and GATHER2 clinical trials, conducted by IVERIC bio, Inc., An Astellas Company. This plain language summary publication shares easy to understand information about a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration which can result in vision loss. Access the #PLSP here: https://lnkd.in/eQTBVHdC.
-
-
Check out the latest from Outcome Capital on the state of #lifesciences: - JPM deal making sets the table for a active 2024 - Rare diseases assets remain M&A target of large strategics, commanding significant premiums and driving billion-dollar deals - #healthtech starts off 2024 on the upswing with transformative acquisitions from Cardinal Health and HCSC - Despite reversion to pre-COVID investment volumes, 2024 began with numerous upsized Series A financings #lifesciences #biotechnology #investmentbanking #meddevice #diagnostics #digitalhealth #pharmaservices #mergersandacquisitions
-
Capsida’s Chakameh Azimpour, Ph.D will be presenting a poster at the 2024 PDA Advanced Therapy Medicinal Products Conference: 📅 Date: 24-25 June 2024 📍 Location: Amsterdam, The Netherlands The poster, entitled "Development of a dual reporter cargo and systemic incorporation of a highly flexible, benchtop automation system to facilitate rAVV9 based novel capsid development and characterization," showcases innovative research that highlights the breadth of Capsida’s analytical development expertise in characterizing novel engineered capsids. This work is a collaborative effort by a talented team of Capsida researchers: Paul Denis, Kevin Chu, Jesse Granados, Regan Sobaje, Claire S., Leandro Fernandez, Tiffany Morrison, Lysa-Anne Volpe, Chakameh Azimpour, Ph.D. Well done to the whole team! #AdvancedTherapies #PDAConference #CapsidDevelopment #BiotechInnovation #ScientificResearch #AutomationInScience #GeneTherapy #ATMP #AdvancedTherapyMedicinalProduct
-
-
🎙️Check out our discussion with Mayukh Sukhatme, MD, President and CIO of Roivant Sciences, about their recent dealmaking and their drug discovery and development philosophy! https://ow.ly/55zJ50PykeY
-
-
Next week I’ll be joining the Ori team at #CGMesa24 in Arizona. Two things you should not miss: 1️⃣ Panel Discussion on Mon, 7th at 7:45 AM: Gain insights into pre-clinical development strategies to help safeguard commercial success. 💡 2️⃣ IRO Platform Demo: See our cutting-edge IRO technology in action. Be sure to book your demo slot before they fill up! 🤖 Please come say hello and let's chat about driving innovation forward, together! #manufacturingbrighterfutures
Heading to Meeting on the Mesa next week? Here's where you can find the Ori team ⬇️ 🧬 Monday October 7 | 7:45 AM – Jason C. Foster, CEO of Ori Biotech, will be chairing a workshop "What can be done during pre-clinical development to avoid commercial failure?" He’ll be joined by: Julie G. Allickson, PhD, Mayo Clinic Bruce Thompson, Kincell Bio Matthew Hewitt, Charles River Laboratories Andrew Snowden, Johnson & Johnson 🤝 Meet the Ori Team – Thomas Heathman, Lee H. Unroe, Kale Feeter, Sarah Haecker Meeks, PhD, Marianna Mavropoulou, Kara Win, Niamh O'Connell, William Raimes will all be attending this year's conference, and are looking forward to connecting with colleagues to discuss the latest advances in CGT manufacturing. Connect with them to arrange a meeting or schedule an IRO demo! 🔍 Live IRO Demos – Visit the 'Camelback' room on the 2nd floor of the Frank Lloyd Wright building for hands-on demos of how IRO® is accelerating product development and Automating Better Biology. Sign up for your hands-on IRO demo ➡️ https://lnkd.in/eZ8sUC4x #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology
-
